Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi

Executive Summary

Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.

You may also be interested in...



Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II

Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.

China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey

After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.

Aurobindo’s Animal Health Acquisition, US Deceleration Surprise Analysts

While its COVID-19 vaccine, partnered with US-based Vaxxinity, is set to move to Phase III trials, Aurobindo has acquired an animal health company as well as several ANDAs and OTC assets. The acquisition and a deceleration in US sales caught analysts by surprise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel